Mar 31 2009
The World Heart Federation, Daiichi Sankyo Company, and Eli Lilly announced today that they have partnered to improve cardiovascular health internationally. The organizations made the announcement at the 58th Annual Scientific Session of the American College of Cardiology in Orlando, Florida.
An estimated 17.5 million people died from cardiovascular disease in 2005, representing 30 percent of all global deaths, making it a significant public health concern.
Through this collaboration, Daiichi Sankyo and Lilly will reinforce the World Heart Federation's efforts addressing the challenges that result from a cardiac event, such as a heart attack or stent placement. In particular, the organizations will work together in emphasizing the importance of a heart healthy lifestyle and adherence to medications for acute coronary syndrome (ACS) patients.
"We find that people who have experienced a cardiac event often struggle to cope with the physical and emotional impact," said Pekka Puska, President of the World Heart Federation. "This collaboration will support patients in making the lifestyle changes that are critical during the recovery process and beyond."
Daiichi Sankyo and Lilly will support activities stemming from the World Heart Federation's 2009 World Heart Day, scheduled to take place on Sunday, September 27 with a focus on workplace wellness.
Acute coronary syndrome (ACS) is an umbrella term that includes unstable angina (chest pain) and myocardial infarction (heart attack). ACS is ultimately the result of coronary heart disease, which is the most severe among cardiovascular diseases.
www.world-heart-federation.org and www.daiichisankyo.com
Extra hour of weekly exercise reduces risk of atrial fibrillation